Nasopharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500

Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the upper part of  throat, behind the nose. This area is called the nasopharynx. The risk factors of nasopharyngeal cancer may include Epstein-Barr virus. Symptoms of nasopharyngeal cancer may include blurry or double vision, difficulty speaking, including hoarseness, ear infections that keep coming back, face pain or numbness, headache, hearing loss, ringing in the ears.

The Nasopharyngeal cancer – Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Nasopharyngeal cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Nasopharyngeal cancer and features dormant and discontinued projects.

Key Targets in the Nasopharyngeal Cancer Pipeline Drugs Market

In the Nasopharyngeal Cancer Pipeline drugs market the key targets are Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Cytotoxic T Lymphocyte Protein 4, Vascular Endothelial Growth Factor Receptor 2, Cells Expressing Latent Membrane Protein 2, Vascular Endothelial Growth Factor Receptor 3, Platelet Derived Growth Factor Receptor Beta, Cells Expressing Latent Membrane Protein 1, Mast/Stem Cell Growth Factor Receptor Kit, and Epstein Barr Nuclear Antigen 1. Programmed Cell Death Protein 1 has the highest number of pipeline products.

Nasopharyngeal Cancer Pipeline Drugs Market, by Targets

Nasopharyngeal Cancer Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key MoA in the Nasopharyngeal Cancer Pipeline Drugs Market

Programmed Cell Death Protein 1 Antagonist has the highest number of pipeline products followed by Programmed Cell Death 1 Ligand 1 Inhibitor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Cytotoxic To Cells Expressing Latent Membrane Protein 2 , Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Platelet Derived Growth Factor Receptor Beta Inhibitor, Cytotoxic To Cells Expressing Latent Membrane Protein 1, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, and Cytotoxic T Lymphocyte Protein 4 Inhibitor.

Nasopharyngeal Cancer Pipeline Drugs Market, by MoA

Nasopharyngeal Cancer Pipeline Drugs Market, by MoA

To get more insights on key MoA, download a free sample report

Nasopharyngeal Cancer Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Nasopharyngeal Cancer Pipeline drugs market are Intravenous, Oral, Intravenous Drip, Parenteral, Subcutaneous, Intraperitoneal, Intralesional, Intrathecal, Intratumor, and Intradermal. Intravenous has the maximum number of pipeline products.

Nasopharyngeal Cancer Pipeline Drugs Market Analysis, by RoA

Nasopharyngeal Cancer Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Nasopharyngeal Cancer Pipeline Drugs Market

In the Nasopharyngeal Cancer Pipeline drugs market the key molecule types are Monoclonal Antibody, Small Molecule, Gene-Modified Cell Therapy, Cell Therapy, Fusion Protein, Monoclonal Antibody Conjugated, Gene Therapy, Biologic, Subunit Vaccine, and Synthetic Peptide.

Nasopharyngeal Cancer Pipeline Drugs Market, by Molecule Types

Nasopharyngeal Cancer Pipeline Drugs Market, by Molecule Types

To get more insights on key molecule types, download a free sample report

Major Companies in the Nasopharyngeal Cancer Pipeline Drugs Market

The major companies in the Nasopharyngeal Cancer Pipeline drugs market are Advenchen Laboratories LLC, Shanghai Junshi Bioscience Co Ltd, Innovent Biologics Inc, Akeso Inc, BeiGene Ltd, Jiangsu Hengrui Medicine Co Ltd, Novartis AG, TCR Cure Biopharma Technology Co Ltd, F. Hoffmann-La Roche Ltd, Ono Pharmaceutical Co Ltd, Xencor Inc, Apollomics Inc, AstraZeneca Plc, Atara Biotherapeutics Inc, and BioSyngen Pte Ltd.

Nasopharyngeal Cancer Pipeline Drugs Market, by Major Companies

Nasopharyngeal Cancer Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Nasopharyngeal Cancer Pipeline Drugs Market Overview

Key Targets Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Cytotoxic T Lymphocyte Protein 4, Vascular Endothelial Growth Factor Receptor 2, Cells Expressing Latent Membrane Protein 2, Vascular Endothelial Growth Factor Receptor 3, Platelet Derived Growth Factor Receptor Beta, Cells Expressing Latent Membrane Protein 1, Mast/Stem Cell Growth Factor Receptor Kit, and Epstein Barr Nuclear Antigen 1
Key Mechanisms of action Programmed Cell Death Protein 1 Antagonist , Programmed Cell Death 1 Ligand 1 Inhibitor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Cytotoxic To Cells Expressing Latent Membrane Protein 2 , Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Platelet Derived Growth Factor Receptor Beta Inhibitor, Cytotoxic To Cells Expressing Latent Membrane Protein 1, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, and Cytotoxic T Lymphocyte Protein 4 Inhibitor
Key Routes of Administration Intravenous, Oral, Intravenous Drip, Parenteral, Subcutaneous, Intraperitoneal, Intralesional, Intrathecal, Intratumor, and Intradermal
Key molecule types Monoclonal Antibody, Small Molecule, Gene-Modified Cell Therapy, Cell Therapy, Fusion Protein, Monoclonal Antibody Conjugated, Gene Therapy, Biologic, Subunit Vaccine, and Synthetic Peptide
Major companies Advenchen Laboratories LLC, Shanghai Junshi Bioscience Co Ltd, Innovent Biologics Inc, Akeso Inc, BeiGene Ltd, Jiangsu Hengrui Medicine Co Ltd, Novartis AG, TCR Cure Biopharma Technology Co Ltd, F. Hoffmann-La Roche Ltd, Ono Pharmaceutical Co Ltd, Xencor Inc, Apollomics Inc, AstraZeneca Plc, Atara Biotherapeutics Inc, and BioSyngen Pte Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngeal cancer
  • The pipeline guide reviews pipeline therapeutics for Nasopharyngeal cancer by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nasopharyngeal cancer therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nasopharyngeal cancer therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Nasopharyngeal cancer

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective countercstrategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nasopharyngeal cancer
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nasopharyngeal Cancer Pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

ADC Therapeutics SA
Advenchen Laboratories LLC
Akeso Inc
Alphamab Oncology
Ambrx Biopharma Inc
Amgen Inc
Apollomics Inc
Ascentage Pharma Group International
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
AVEO Pharmaceuticals Inc
BeiGene Ltd
Biomics Biotechnologies Co Ltd
BioSyngen Pte Ltd
BP InnoMed Ltd
Bristol-Myers Squibb Co
Chengdu Wonho Biology Engineering Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
China Immunotech Co Ltd
Compugen Ltd
Eli Lilly and Co
EpimAb Biotherapeutics Inc
Eutilex Co Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
Geneius Biotechnology Inc
GenFleet Therapeutics (Shanghai) Inc
Genrix (Shanghai) Biopharmaceutical Co Ltd
GeoVax Labs Inc
GlaxoSmithKline Plc
Guangzhou Bairui Biomedical Technology Co Ltd
Guangzhou Doublle Bioproduct Inc
Harbin Gloria Pharmaceuticals Co Ltd
HRYZ (ShenZhen) Biotech Co
Huabo Biopharm (Shanghai) Co Ltd
Immix BioPharma Inc
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Immunomic Therapeutics Inc
Incyte Corp
Inhibrx Inc
Inmune Bio Inc
Innovent Biologics Inc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Joint Biosciences Ltd
Karyopharm Therapeutics Inc
Kuur Therapeutics Ltd
Lion TCR Pte Ltd
Merck & Co Inc
Merck KGaA
Molecular Targeting Technologies Inc
Neonc Technologies Inc
Novartis AG
Ono Pharmaceutical Co Ltd
Oxford Vacmedix UK Ltd
Polaris Pharmaceuticals Inc
Qilu Puget Sound Biotherapeutics Corp
Rapa Therapeutics LLC
RAPT Therapeutics Inc
Rubius Therapeutics Inc
Seven and Eight Biopharmaceuticals Corp
Shanghai De Novo Pharmatech Co Ltd
Shanghai GeneChem Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Miracogen Inc
Shenghe (China) Biopharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Soricimed Biopharma Inc
Suzhou Zelgen Biopharmaceutical Co Ltd
TCR Cure Biopharma Technology Co Ltd
Tessa Therapeutics Ltd
TOT Biopharm Co Ltd
Transcenta Holding Ltd
Vectorite Biomedical Inc
Viracta Therapeutics Inc
Xencor Inc
Xiangxue Life Sciences
Y-Biologics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Nasopharyngeal Cancer – Overview

Nasopharyngeal Cancer – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Nasopharyngeal Cancer – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nasopharyngeal Cancer – Companies Involved in Therapeutics Development

Nasopharyngeal Cancer – Drug Profiles

Nasopharyngeal Cancer – Dormant Projects

Nasopharyngeal Cancer – Discontinued Products

Nasopharyngeal Cancer – Product Development Milestones

Featured News & Press Releases

Apr 19, 2022: BeiGene presents updated results from phase 3 RATIONALE-309 Trial of PD-1 inhibitor Tislelizumab in first-line RM-NPC in Virtual ASCO Plenary Series

Apr 08, 2022: Junshi Biosciences and Coherus present results of phase 3 study of toripalimab in first line treatment of recurrent or metastatic nasopharyngeal carcinoma at 2022 AACR Annual Meeting

Mar 07, 2022: Voluntary announcement – JS001sc injection received the clinical trial approval

Dec 10, 2021: BeiGene presents results from phase 3 trial of Tislelizumab in nasopharyngeal cancer at ESMO Immuno-Oncology Congress 2021

Dec 03, 2021: Junshi Biosciences announces two additional indications for toripalimab included in China’s National Reimbursement Drug List

Dec 02, 2021: BeiGene to present new clinical data on Tislelizumab at ESMO IO Congress 2021

Nov 29, 2021: Junshi Biosciences announces approval of supplemental new drug application by NMPA for Toripalimab in combination with Cisplatin and Gemcitabine as first-line treatment for patients with locally recurrent or metastatic nasopharyngeal carcinoma

Nov 20, 2021: Sichuan Kelun Pharmaceutical Co : Announcement on the acceptance of the listing application for PD-L1 new drug Tetlizumab injection by NMPA

Nov 01, 2021: Coherus and Junshi Biosciences announce FDA acceptance of BLA filing for toripalimab for treatment of nasopharyngeal carcinoma

Oct 31, 2021: Shanghai Junshi Bioscience Co: Voluntary announcement -the FDA accepted biologics license application of Toripalimab for treatment of nasopharyngeal carcinoma

Oct 06, 2021: Viracta Therapeutics initiates phase 1b/2 trial in Epstein-Barr Virus-Positive (EBV+) solid tumors

Sep 20, 2021: Pembrolizumab does not prolong overall survival compared to chemotherapy in platinum-pretreated recurrent or metastatic nasopharyngeal carcinoma

Sep 15, 2021: Coherus and Junshi Biosciences announce results from phase 3 study of toripalimab published in September Issue of Nature Medicine

Sep 01, 2021: Coherus and Junshi Biosciences announce completion of rolling BLA submission to U.S. FDA for toripalimab for the treatment of nasopharyngeal carcinoma

Aug 22, 2021: BeiGene announces acceptance of a supplemental biologics license application in China for tislelizumab in nasopharyngeal cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Nasopharyngeal Cancer, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Nasopharyngeal Cancer – Pipeline by ADC Therapeutics SA, 2022

Nasopharyngeal Cancer – Pipeline by Advenchen Laboratories LLC, 2022

Nasopharyngeal Cancer – Pipeline by Akeso Inc, 2022

Nasopharyngeal Cancer – Pipeline by Alphamab Oncology, 2022

Nasopharyngeal Cancer – Pipeline by Ambrx Biopharma Inc, 2022

Nasopharyngeal Cancer – Pipeline by Amgen Inc, 2022

Nasopharyngeal Cancer – Pipeline by Apollomics Inc, 2022

Nasopharyngeal Cancer – Pipeline by Ascentage Pharma Group International, 2022

Nasopharyngeal Cancer – Pipeline by Astex Pharmaceuticals Inc, 2022

Nasopharyngeal Cancer – Pipeline by AstraZeneca Plc, 2022

Nasopharyngeal Cancer – Pipeline by Atara Biotherapeutics Inc, 2022

Nasopharyngeal Cancer – Pipeline by AVEO Pharmaceuticals Inc, 2022

Nasopharyngeal Cancer – Pipeline by BeiGene Ltd, 2022

Nasopharyngeal Cancer – Pipeline by Biomics Biotechnologies Co Ltd, 2022

Nasopharyngeal Cancer – Pipeline by BioSyngen Pte Ltd, 2022

Nasopharyngeal Cancer – Pipeline by BP InnoMed Ltd, 2022

Nasopharyngeal Cancer – Pipeline by Bristol-Myers Squibb Co, 2022

Nasopharyngeal Cancer – Pipeline by Chengdu Wonho Biology Engineering Co Ltd, 2022

Nasopharyngeal Cancer – Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022

Nasopharyngeal Cancer – Pipeline by China Immunotech Co Ltd, 2022

Nasopharyngeal Cancer – Pipeline by Compugen Ltd, 2022

Nasopharyngeal Cancer – Pipeline by Eli Lilly and Co, 2022

Nasopharyngeal Cancer – Pipeline by EpimAb Biotherapeutics Inc, 2022

Nasopharyngeal Cancer – Pipeline by Eutilex Co Ltd, 2022

Nasopharyngeal Cancer – Pipeline by Exelixis Inc, 2022

Nasopharyngeal Cancer – Pipeline by F. Hoffmann-La Roche Ltd, 2022

Nasopharyngeal Cancer – Pipeline by Geneius Biotechnology Inc, 2022

Nasopharyngeal Cancer – Pipeline by GenFleet Therapeutics (Shanghai) Inc, 2022

Nasopharyngeal Cancer – Pipeline by Genrix (Shanghai) Biopharmaceutical Co Ltd, 2022

Nasopharyngeal Cancer – Pipeline by GeoVax Labs Inc, 2022

Nasopharyngeal Cancer – Pipeline by GlaxoSmithKline Plc, 2022

Nasopharyngeal Cancer – Pipeline by Guangzhou Bairui Biomedical Technology Co Ltd, 2022

Nasopharyngeal Cancer – Pipeline by Guangzhou Doublle Bioproduct Inc, 2022

Nasopharyngeal Cancer – Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, 2022

Nasopharyngeal Cancer – Pipeline by HRYZ (ShenZhen) Biotech Co, 2022

Nasopharyngeal Cancer – Pipeline by Huabo Biopharm (Shanghai) Co Ltd, 2022

Nasopharyngeal Cancer – Pipeline by Immix BioPharma Inc, 2022

Nasopharyngeal Cancer – Pipeline by ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd, 2022

Nasopharyngeal Cancer – Pipeline by Immunomic Therapeutics Inc, 2022

Nasopharyngeal Cancer – Pipeline by Incyte Corp, 2022

Nasopharyngeal Cancer – Pipeline by Inhibrx Inc, 2022

Nasopharyngeal Cancer – Pipeline by Inmune Bio Inc, 2022

Nasopharyngeal Cancer – Pipeline by Innovent Biologics Inc, 2022

Nasopharyngeal Cancer – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Nasopharyngeal Cancer – Pipeline by Johnson & Johnson, 2022

Nasopharyngeal Cancer – Pipeline by Joint Biosciences Ltd, 2022

Nasopharyngeal Cancer – Pipeline by Karyopharm Therapeutics Inc, 2022

Nasopharyngeal Cancer – Pipeline by Kuur Therapeutics Ltd, 2022

Nasopharyngeal Cancer – Pipeline by Lion TCR Pte Ltd, 2022

Nasopharyngeal Cancer – Pipeline by Merck & Co Inc, 2022

Nasopharyngeal Cancer – Pipeline by Merck KGaA, 2022

Nasopharyngeal Cancer – Pipeline by Molecular Targeting Technologies Inc, 2022

Nasopharyngeal Cancer – Pipeline by Neonc Technologies Inc, 2022

Nasopharyngeal Cancer – Pipeline by Novartis AG, 2022

Nasopharyngeal Cancer – Pipeline by Ono Pharmaceutical Co Ltd, 2022

Nasopharyngeal Cancer – Pipeline by Oxford Vacmedix UK Ltd, 2022

Nasopharyngeal Cancer – Pipeline by Polaris Pharmaceuticals Inc, 2022

Nasopharyngeal Cancer – Pipeline by Qilu Puget Sound Biotherapeutics Corp, 2022

Nasopharyngeal Cancer – Pipeline by Rapa Therapeutics LLC, 2022

Nasopharyngeal Cancer – Pipeline by RAPT Therapeutics Inc, 2022

Nasopharyngeal Cancer – Pipeline by Rubius Therapeutics Inc, 2022

Nasopharyngeal Cancer – Pipeline by Seven and Eight Biopharmaceuticals Corp, 2022

Nasopharyngeal Cancer – Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2022

Nasopharyngeal Cancer – Pipeline by Shanghai GeneChem Co Ltd, 2022

Nasopharyngeal Cancer – Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022

Nasopharyngeal Cancer – Pipeline by Shanghai Miracogen Inc, 2022

Nasopharyngeal Cancer – Pipeline by Shenghe (China) Biopharmaceutical Co Ltd, 2022

Nasopharyngeal Cancer – Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, 2022

Nasopharyngeal Cancer – Pipeline by Soricimed Biopharma Inc, 2022

Nasopharyngeal Cancer – Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2022

Nasopharyngeal Cancer – Pipeline by TCR Cure Biopharma Technology Co Ltd, 2022

Nasopharyngeal Cancer – Pipeline by Tessa Therapeutics Ltd, 2022

Nasopharyngeal Cancer – Pipeline by TOT Biopharm Co Ltd, 2022

Nasopharyngeal Cancer – Pipeline by Transcenta Holding Ltd, 2022

Nasopharyngeal Cancer – Pipeline by Vectorite Biomedical Inc, 2022

Nasopharyngeal Cancer – Pipeline by Viracta Therapeutics Inc, 2022

Nasopharyngeal Cancer – Pipeline by Xencor Inc, 2022

Nasopharyngeal Cancer – Pipeline by Xiangxue Life Sciences, 2022

Nasopharyngeal Cancer – Pipeline by Y-Biologics Inc, 2022

Nasopharyngeal Cancer – Dormant Projects, 2022

Nasopharyngeal Cancer – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Nasopharyngeal Cancer, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

  • What are the key targets in the Nasopharyngeal Cancer Pipeline drugs market?

    In the Nasopharyngeal Cancer Pipeline drugs market the key targets are Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Cytotoxic T Lymphocyte Protein 4, Vascular Endothelial Growth Factor Receptor 2, Cells Expressing Latent Membrane Protein 2, Vascular Endothelial Growth Factor Receptor 3, Platelet Derived Growth Factor Receptor Beta, Cells Expressing Latent Membrane Protein 1, Mast/Stem Cell Growth Factor Receptor Kit, and Epstein Barr Nuclear Antigen 1.

  • What are the key mechanisms of action in the Nasopharyngeal Cancer Pipeline drugs market?

    In the Nasopharyngeal Cancer Pipeline drugs market the key mechanisms of action are Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Cytotoxic To Cells Expressing Latent Membrane Protein 2 , Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Platelet Derived Growth Factor Receptor Beta Inhibitor, Cytotoxic To Cells Expressing Latent Membrane Protein 1, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, and Cytotoxic T Lymphocyte Protein 4 Inhibitor.

  • What are the key routes of administration in the Nasopharyngeal Cancer Pipeline drugs market?

    The key routes of administration in the Nasopharyngeal Cancer Pipeline drugs market are Intravenous, Oral, Intravenous Drip, Parenteral, Subcutaneous, Intraperitoneal, Intralesional, Intrathecal, Intratumor, and Intradermal.

  • What are the key molecule types in the Nasopharyngeal Cancer Pipeline drugs market?

    The key molecule types in the Nasopharyngeal Cancer Pipeline drugs market are Monoclonal Antibody, Small Molecule, Gene-Modified Cell Therapy, Cell Therapy, Fusion Protein, Monoclonal Antibody Conjugated, Gene Therapy, Biologic, Subunit Vaccine, and Synthetic Peptide.

  • What are the major companies in the Nasopharyngeal Cancer Pipeline drugs market?

    In the Nasopharyngeal Cancer Pipeline drugs market the major companies are Advenchen Laboratories LLC, Shanghai Junshi Bioscience Co Ltd, Innovent Biologics Inc, Akeso Inc, BeiGene Ltd, Jiangsu Hengrui Medicine Co Ltd, Novartis AG, TCR Cure Biopharma Technology Co Ltd, F. Hoffmann-La Roche Ltd, Ono Pharmaceutical Co Ltd, Xencor Inc, Apollomics Inc, AstraZeneca Plc, Atara Biotherapeutics Inc, and BioSyngen Pte Ltd.

Nasopharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Nasopharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Nasopharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.